ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Common Equity of $61.3 million for Q1 2026, down 46.34% sequentially from $114.3 million in Q4 2025, and down 73.22% YoY from $229.0 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Common Equity for 7 years, with the latest figure at $61.3 million in Q1 2026.
- Quarterly Common Equity fell 73.22% year-over-year to $61.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.3 million (down 73.22% YoY) and the FY2025 annual result came in at $114.3 million, down 55.51% from the prior year.
- Common Equity declined to $61.3 million in Q1 2026 per SPRY's latest filing, from $114.3 million in the prior quarter.
- Over five years, Common Equity peaked at $272.9 million in Q4 2022 and troughed at -$50.2 million in Q3 2022.
- A 5-year average of $162.3 million and a median of $215.2 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 972.7% in 2022, down 115.1% in 2022.
- Over 5 years, Common Equity stood at $272.9 million in 2022, then slipped by 15.44% to $230.8 million in 2023, then grew by 11.28% to $256.8 million in 2024, then sank by 55.51% to $114.3 million in 2025, then sank by 46.34% to $61.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $61.3 million, $114.3 million, and $147.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 12.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.51 Mn |
| Mar 31, 2026 | 61.31 Mn |
| Dec 31, 2025 | 114.26 Mn |
| Sep 30, 2025 | 147.66 Mn |
| Jun 30, 2025 | 192.32 Mn |
| Mar 31, 2025 | 228.97 Mn |
| Dec 31, 2024 | 256.80 Mn |
| Sep 30, 2024 | 200.98 Mn |
| Jun 30, 2024 | 215.24 Mn |
| Mar 31, 2024 | 223.87 Mn |
| Dec 31, 2023 | 230.76 Mn |
| Sep 30, 2023 | 237.28 Mn |
| Jun 30, 2023 | 248.55 Mn |
| Mar 31, 2023 | 261.16 Mn |
| Dec 31, 2022 | 272.89 Mn |
| Sep 30, 2022 | -50.16 Mn |
| Jun 30, 2022 | -44.03 Mn |
| Mar 31, 2022 | -38.26 Mn |
| Dec 31, 2021 | -31.27 Mn |
| Sep 30, 2021 | 332.13 Mn |